Sagimet Biosciences (SGMT) announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in patients with advanced fibrosis will be presented at the American Association for the Study of Liver Disease – The Liver Meeting 2025, taking place November 7-11, 2025 in Washington, DC. The analysis showed denifanstat’s robust anti-fibrotic effect as measured by both conventional and AI-based digital pathology. AI-based digital pathology was utilized to identify a subpopulation of MASH patients with advanced baseline fibrosis and enabled the observation that denifanstat reduced fibrosis and improved multiple non-invasive test biomarkers associated with the primary drivers of MASH in this subgroup.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential
- Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom
- Sagimet Biosciences reports data from Phase 3 trial on denifanstat
- Sagimet Biosciences announces presentations at MASH Drug Development Summit
- Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy